Sign in
4

Changes in Ownership

AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000036

Chief Commercial Officer sold 2,868 shares at $28.96 ($83,057)

  • Chief Commercial Officer acquired 9,666 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Milanova Tsveta · Chief Commercial Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-02 Exercise or conversion : show line 1 in the form 10b5-1 +5,666 40,459 D
2026-03-02 Sale : show line 2 in the form 10b5-1 −1,681 $28.96 $48,682 38,778 D
2026-03-02 Exercise or conversion : show line 3 in the form 10b5-1 +4,000 42,778 D
2026-03-02 Sale : show line 4 in the form 10b5-1 −1,187 $28.96 $34,376 41,591 D
Open-market sales · 2,868 sh · avg $28.96 · $83,057

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2026-03-01 Grant or award : show line 5 in the form 10b5-1 Restricted stock units +14,000 14,000 D
2026-03-01 Grant or award : show line 6 in the form 10b5-1 Stock options (right to buy) +52,000 52,000 D
2026-03-02 Exercise or conversion : show line 7 in the form 10b5-1 Restricted stock units −5,666 5,667 D
2026-03-02 Exercise or conversion : show line 8 in the form 10b5-1 Restricted stock units −4,000 8,000 D
Loading xslF345X05/wk-form4_1772572436.xml…